Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY900014 versus insulin lispro (Humalog) in Japanese patients with type 1 diabetes mellitus
jRCT2080223803Phase 1Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of insulin lispro in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Pharmacokinetics of LY900014 vs insulin lispro and Glucodynamic effects of LY900014 vs insulin lispro. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
insulin lispro
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCT2080223803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223803.